Latest news with #IzotropicCorporation
Yahoo
7 days ago
- Business
- Yahoo
Izotropic Introduces New Corporate Website & Brand Identity
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - August 12, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of its new corporate website and refreshed brand identity. The Company's redesigned website, reflects Izotropic's refined corporate positioning and introduces a modern, unique, visual identity that emphasizes its focus on people- patients, clinicians, and stakeholders across the healthcare ecosystem. The site provides an accessible, centralized platform for engaging with Izotropic's story, solutions, and strategy as the Company builds toward commercialization. The updated web presence features streamlined navigation and enriched content, including new presentations, video materials, and messaging that communicates Izotropic's value proposition, clinical direction, and strategic focus. As part of the broader brand system, Izotropic has also introduced a corporate tagline: "Advanced Imaging. Accessible Care.", which appears in materials and corporate communications to communicate the Company's commitment to innovations that can scale across diverse care settings. The Company's flagship product, the IzoView Breast CT Imaging System, carries a new distinct tagline: "Engineered for Today's Challenges and Tomorrow's Care Models.", highlighting its ability to address unmet needs in breast imaging, while capturing its alignment with evolving industry trends driving market expansion. Izotropic invites investors, media, and stakeholders to explore the new site and follow the Company's progress as it works to deliver transformative solutions to the global breast imaging market. About Izotropic: More information about Izotropic Corporation can be found on its website at and by reviewing its profile on SEDAR at Forward-Looking Statements: This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale. Contacts: Robert Thast, Interim Chief Executive OfficerTelephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1Email: bthast@ James Gagnon, International CommunicationsTelephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2 General and Corporate InquiriesTelephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3Email: info@ Corporate CommunicationsIBNAustin, OfficeEditor@ To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-08-2025
- Business
- Yahoo
Izotropic Launches Podcast Episode #1: Beyond the Mammogram: Rethinking the Future of Breast Imaging
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ('Izotropic', or the 'Company'), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of its new podcast series. The first episode Beyond the Mammogram: Rethinking the Future of Breast Imaging is now available in English, Arabic, Chinese, French, German, Italian and Spanish. The podcast marks a new initiative in the Company's ongoing mission to inform and engage broader global audiences about innovations in breast imaging. Through accessible and engaging conversations, the series will explore the evolving landscape of breast cancer detection, highlighting clinical challenges, market dynamics, and the technologies poised to reshape the industry and patient care. In the premiere episode, listeners will hear a compelling discussion about the limitations of current imaging tools, including mammography, digital breast tomosynthesis, ultrasound, and MRI, particularly in screening women with dense breast tissue, who represent approximately 50% of the population. With breast cancer projected to affect over 315,000 women in the U.S. in 2025, the episode highlights the urgent need for imaging technologies that offer earlier, more accurate detection and a better patient experience. The podcast draws on insights from recent industry data, regulatory updates, and the Company's own developments, offering a fresh perspective on Izotropic's mission and its flagship product, IzoView, a first-of-its-kind dedicated Breast CT Imaging System. This new communications platform repackages publicly disclosed information into a conversational format that's both educational and accessible to patients, healthcare professionals, and stakeholders across the breast health ecosystem. The Company intends to use the podcast to support broader awareness-building efforts as it advances IzoView toward regulatory approval and market launch. Episode 1 of the podcast is available now on the Company's YouTube channel. Subscribe to stay informed about future episodes covering breast imaging trends, patient advocacy, and medical imaging innovation. Podcast Sources Cited: Izotropic Corporation (July 29, 2025) Izotropic's IzoView Breast CT Device Stands Distinct vs Existing Breast Imaging Technologies. [Press Release]. Izotropic Corporation (August 5, 2025) Izotropic's IzoView Positioned to Capitalize on Key Global Breast Imaging Market Drivers [Press Release]. Murphy, H. (2025, July 10). Over 100 AI-enabled radiology algorithms added to FDA's list of approvals. Health Imaging. Retrieved July 14, 2025, from Carey, L. (2025, July 14). Radiology drives July FDA AI-enabled medical device update. Retrieved July 14, 2025, from Allegretto, A. (2025, July 14). Rural women more prone to advanced-stage breast cancer. Retrieved July 14, 2025, from Murphy, H. (2025, July 16). Reimbursement for contrast-enhanced mammography is on the rise. Health Imaging. Retrieved July 16, 2025, from Murphy, H. (2025, July 15). GPT-4o's 'all or nothing' accuracy continues to hinder its radiologic capabilities. Health Imaging. Retrieved July 16, 2025, from About Izotropic: More information about Izotropic Corporation can be found on its website at and by reviewing its profile on SEDAR at Disclaimer & Forward-Looking Statements:This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for episodes are generated with the assistance of Google AI. Content was produced using generative tools and may contain machine-generated elements. Listeners are encouraged to verify all information through official sources. Contacts: Robert Thast, Interim Chief Executive Officer Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1 Email: bthast@ James Gagnon, International Communications Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2 General and Corporate Inquiries Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3 Email: info@ Corporate CommunicationsIBNAustin, OfficeEditor@ in to access your portfolio
Toronto Star
07-08-2025
- Business
- Toronto Star
Izotropic Launches Podcast Episode #1: Beyond the Mammogram: Rethinking the Future of Breast Imaging
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ('Izotropic', or the 'Company'), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of its new podcast series. The first episode Beyond the Mammogram: Rethinking the Future of Breast Imaging is now available in English, Arabic, Chinese, French, German, Italian and Spanish. The podcast marks a new initiative in the Company's ongoing mission to inform and engage broader global audiences about innovations in breast imaging. Through accessible and engaging conversations, the series will explore the evolving landscape of breast cancer detection, highlighting clinical challenges, market dynamics, and the technologies poised to reshape the industry and patient care. In the premiere episode, listeners will hear a compelling discussion about the limitations of current imaging tools, including mammography, digital breast tomosynthesis, ultrasound, and MRI, particularly in screening women with dense breast tissue, who represent approximately 50% of the population. With breast cancer projected to affect over 315,000 women in the U.S. in 2025, the episode highlights the urgent need for imaging technologies that offer earlier, more accurate detection and a better patient experience. ARTICLE CONTINUES BELOW The podcast draws on insights from recent industry data, regulatory updates, and the Company's own developments, offering a fresh perspective on Izotropic's mission and its flagship product, IzoView, a first-of-its-kind dedicated Breast CT Imaging System. This new communications platform repackages publicly disclosed information into a conversational format that's both educational and accessible to patients, healthcare professionals, and stakeholders across the breast health ecosystem. The Company intends to use the podcast to support broader awareness-building efforts as it advances IzoView toward regulatory approval and market launch. Episode 1 of the podcast is available now on the Company's YouTube channel. Subscribe to stay informed about future episodes covering breast imaging trends, patient advocacy, and medical imaging innovation. Podcast Sources Cited: Izotropic Corporation (July 29, 2025) Izotropic's IzoView Breast CT Device Stands Distinct vs Existing Breast Imaging Technologies. [Press Release]. Izotropic Corporation (August 5, 2025) Izotropic's IzoView Positioned to Capitalize on Key Global Breast Imaging Market Drivers [Press Release]. Izotropic Corporation (July 29, 2025) Izotropic's IzoView Breast CT Device Stands Distinct vs Existing Breast Imaging Technologies. [Press Release]. Izotropic Corporation (August 5, 2025) Izotropic's IzoView Positioned to Capitalize on Key Global Breast Imaging Market Drivers [Press Release]. Murphy, H. (2025, July 10). Over 100 AI-enabled radiology algorithms added to FDA's list of approvals. Health Imaging. Retrieved July 14, 2025, from Carey, L. (2025, July 14). Radiology drives July FDA AI-enabled medical device update. Retrieved July 14, 2025, from Allegretto, A. (2025, July 14). Rural women more prone to advanced-stage breast cancer. Retrieved July 14, 2025, from Murphy, H. (2025, July 16). Reimbursement for contrast-enhanced mammography is on the rise. Health Imaging. Retrieved July 16, 2025, from Murphy, H. (2025, July 15). GPT-4o's 'all or nothing' accuracy continues to hinder its radiologic capabilities. Health Imaging. Retrieved July 16, 2025, from About Izotropic: More information about Izotropic Corporation can be found on its website at and by reviewing its profile on SEDAR at Disclaimer & Forward-Looking Statements: This document may contain statements that are 'Forward-Looking Statements,' which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as 'anticipate,' 'believe,' 'envision,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'predict,' 'project,' 'target,' 'potential,' 'will,' 'would,' 'could,' 'should,' 'continue,' 'contemplate' and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale. ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW Podcast episodes are generated with the assistance of Google AI. Content was produced using generative tools and may contain machine-generated elements. Listeners are encouraged to verify all information through official sources. Contacts: Robert Thast, Interim Chief Executive Officer Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1 Email: bthast@ James Gagnon, International Communications Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2 General and Corporate Inquiries Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3 Email: info@ Corporate Communications IBN Austin, Texas 512.354.7000 Office Editor@
